Novo Nordisk’s Obesity Setback: What Kagrama’s Miss vs. Zepbound Means for Investors
March 5, 2026
A surprising obesity trial result has shaken confidence in Novo Nordisk (NVO +1.38%) and sharpened the spotlight on Eli Lilly (LLY 2.03%) in this fiercely competitive GLP‑1 race. Watch the video below to see what it could mean for investors.
*This video was published on Feb.24, 2026.
Andy Cross has no position in any of the stocks mentioned. Loren Horst has positions in Novo Nordisk. Nicholas Sciple has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Search
RECENT PRESS RELEASES
Related Post
